# Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive

> **NCT03992170** · PHASE2 · UNKNOWN · sponsor: **Azienda Ospedaliera Universitaria Senese** · enrollment: 50 (estimated)

## Conditions studied

- Myeloma Multiple

## Interventions

- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT03992170
- **Lead sponsor:** Azienda Ospedaliera Universitaria Senese
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-31
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-06-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03992170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03992170, "Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03992170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*